Get the Stockscreener App
26.23
4.18%
-1.145
After Hours:
26.39
0.16
+0.61%
Novocure Ltd stock is traded at $26.23, with a volume of 1.01M.
It is down -4.18% in the last 24 hours and down -21.49% over the past month.
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
See More
Previous Close:
$27.38
Open:
$27.22
24h Volume:
1.01M
Relative Volume:
0.76
Market Cap:
$2.84B
Revenue:
$577.74M
Net Income/Loss:
$-149.78M
P/E Ratio:
-18.74
EPS:
-1.4
Net Cash Flow:
$-78.21M
1W Performance:
-9.58%
1M Performance:
-21.49%
6M Performance:
+45.88%
1Y Performance:
+95.89%
1-Day Range:
$26.15
$27.59
1-Week Range:
$26.15
$29.29
52-Week Range:
$11.70
$34.13
Novocure Ltd Stock (NVCR) Company Profile
Name
Novocure Ltd
Sector
Industry
Phone
44 (0)15 3475 6700
Address
NO. 4 THE FORUM, ST. HELIER
Compare NVCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
26.23 | 2.84B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
113.02 | 196.03B | 41.22B | 5.77B | 6.49B | 3.29 |
|
BSX
Boston Scientific Corp
|
95.65 | 140.97B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
362.80 | 138.31B | 21.97B | 3.59B | 3.21B | 9.33 |
|
MDT
Medtronic Plc
|
85.25 | 109.31B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
71.04 | 41.90B | 6.60B | 4.16B | 490.10M | 6.93 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-28-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-08-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-04-23 | Initiated | SVB Securities | Outperform |
| Jul-31-23 | Upgrade | Evercore ISI | Underperform → In-line |
| Jun-07-23 | Upgrade | Wedbush | Underperform → Neutral |
| May-16-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-06-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-05-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-29-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-24-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-05-22 | Downgrade | Evercore ISI | In-line → Underperform |
| May-16-22 | Initiated | H.C. Wainwright | Buy |
| Feb-08-22 | Initiated | Loop Capital | Buy |
| Feb-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| Jan-03-22 | Upgrade | Evercore ISI | Underperform → In-line |
| Jul-01-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-14-21 | Downgrade | Wedbush | Neutral → Underperform |
| Jan-25-21 | Reiterated | Piper Sandler | Overweight |
| Sep-23-20 | Initiated | Northland Capital | Outperform |
| Sep-18-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-17-20 | Downgrade | Truist | Buy → Hold |
| Jun-01-20 | Resumed | Oppenheimer | Perform |
| May-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-09-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Mar-05-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-29-19 | Upgrade | SunTrust | Hold → Buy |
| Jul-26-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-19 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-20-19 | Initiated | SunTrust | Hold |
| Nov-02-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jul-16-18 | Initiated | Evercore ISI | Outperform |
| Apr-18-18 | Reiterated | Mizuho | Buy |
| Feb-23-18 | Reiterated | Mizuho | Buy |
| May-24-17 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Jul-29-16 | Reiterated | Wedbush | Outperform |
| Jan-19-16 | Initiated | Barclays | Underweight |
| Dec-02-15 | Initiated | Deutsche Bank | Hold |
View All
Novocure Ltd Stock (NVCR) Latest News
NovoCure Ltd (NVCR) Shares Down 3.67% on Jan 14 - GuruFocus.com
NovoCure (NASDAQ:NVCR) Earns "Buy" Rating from HC Wainwright - MarketBeat
Deep Dive Into NovoCure Stock: Analyst Perspectives (7 Ratings) - Benzinga
NovoCure’s (NVCR) Neutral Rating Reaffirmed at Wedbush - Defense World
NovoCure's (NVCR) Neutral Rating Reiterated at Wedbush - MarketBeat
Is Now The Time To Buy NovoCure Ltd (NASDAQ: NVCR) Stock? - Stocks Register
Novocure reports revenue growth, FDA approvals in 2024 - Investing.com India
Novocure Reports Strong 19% Revenue Growth, Hits $605M as Cancer Treatment Platform Expands - StockTitan
Investing in NovoCure (NASDAQ:NVCR) a year ago would have delivered you a 97% gain - Simply Wall St
NovoCure Limited (NASDAQ:NVCR) Shares Acquired by Versant Capital Management Inc - Defense World
NovoCure Limited (NASDAQ:NVCR) Receives $32.67 Average PT from Brokerages - MarketBeat
NovoCure Limited (NASDAQ:NVCR) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Novocure CEO to Present at J.P. Morgan Healthcare Conference, Announces Investor Meetings - StockTitan
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference - Yahoo Finance
NovoCure Limited (NASDAQ:NVCR) Shares Acquired by Franklin Resources Inc. - MarketBeat
Geode Capital Management LLC Acquires 29,871 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World
NovoCure (NASDAQ:NVCR) Reaches New 12-Month HighShould You Buy? - MarketBeat
Research Analysts’ Recent Ratings Updates for NovoCure (NVCR) - Defense World
Tumor Treating Fields Market Growth in Future Scope 2024-2031 | Novocure GmbH and Zai Lab - openPR
Novocure's SWOT analysis: oncology med-tech firm's stock faces growth challenges By Investing.com - Investing.com South Africa
Novocure's SWOT analysis: oncology med-tech firm's stock faces growth challenges - Investing.com
NovoCure (NASDAQ:NVCR) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World
Novocure Stock Hits 52-Week High at $32.65 Amidst Strong Yearly Growth - Investing.com Australia
NovoCure (NASDAQ:NVCR) Shares Gap Up on Analyst Upgrade - MarketBeat
Novocure price target raised to $42 from $28 at Piper Sandler - Yahoo Finance
Novocure Stock Hits 52-Week High at $32.65 Amidst Strong Yearly Growth By Investing.com - Investing.com South Africa
NovoCure (NASDAQ:NVCR) Price Target Raised to $42.00 - MarketBeat
Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction. - MSN
Brokerages Set NovoCure Limited (NASDAQ:NVCR) Target Price at $30.33 - MarketBeat
Quantinno Capital Management LP Cuts Position in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
47,034 Shares in NovoCure Limited (NASDAQ:NVCR) Bought by Weiss Asset Management LP - MarketBeat
NovoCure (NASDAQ:NVCR) Shares Gap UpHere's Why - MarketBeat
Holocene Advisors LP Purchases 22,276 Shares of NovoCure Limited (NASDAQ:NVCR) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stake in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
MetLife Investment Management LLC Has $963,000 Holdings in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
Why NovoCure Stock Was Winning Big This Week - Mitrade
BNP Paribas Financial Markets Has $2.75 Million Stock Position in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025? - sharewise
CORRECTING and REPLACING – Novocure to Report Third Quarter 2016 Financial Results - Marketscreener.com
Edgestream Partners L.P. Takes Position in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
Intech Investment Management LLC Makes New Investment in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
NovoCure Target of Unusually Large Options Trading (NASDAQ:NVCR) - Defense World
Novocure Stock Earns 96 RS Rating - Yahoo! Voices
NovoCure stock target increased on positive trial results By Investing.com - Investing.com Nigeria
NovoCure stock target increased on positive trial results - Investing.com
Novocure reports positive phase 3 results for tumor treating fields therapy - OutSourcing-Pharma.com
NVCR Stock Up as TTFields Therapy Meets Pancreatic Cancer Study Goals - Yahoo Finance
Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint - Yahoo Finance
NovoCure Limited (NASDAQ:NVCR) Looks Just Right With A 84% Price Jump - Simply Wall St
Novocure stock hits 52-week high at $28.26 amid robust growth - Investing.com Canada
Bridgewater Associates LP Sells 41,898 Shares of NovoCure Limited (NASDAQ:NVCR) - MarketBeat
Novocure Ltd Stock (NVCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.10%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):